Whole‐body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study
Cancer · 2023
DOI: 10.1002/cncr.34631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Meis Omran und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Li-Fraumeni Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
To evaluate the psychosocial consequences of surveillance with whole‐body MRI (WB‐MRI) in individuals with the heritable TP53 ‐related cancer (h TP53 rc) syndrome, also known as the Li‐Fraumeni syndrome, with regard to cancer worry, perceived benefits and risks to surveillance and overall health. Patients and methods Since 2016, the national Swedish TP53 Study (SWEP53) has offered surveillance with WB‐MRI to all individuals with h TP53 rc syndrome. Seventy‐five individuals have been included in the study. Sixty consecutive participants fulfilled a base‐line evaluation as well as an evaluation after 1 year with structured questionnaires including the Cancer Worry Scale (CWS), perceived benefits and risks of surveillance, and the 36‐item Short Form Survey (SF‐36). Individuals with or without previous personal cancer diagnosis were enrolled and results at baseline and after 1 year of surveillance were compared. For SF‐36, a comparison with the normal population was also made.
Results
Participants with previous cancer tend to worry more about cancer, but both individuals with and without cancer had a positive attitude toward surveillance with no differences regarding perceived benefits and barriers to surveillance. Participants with a previous cancer scored significantly lower on some of the SF‐36 subscales, but between‐group differences were found only for social functioning after 1 year.
Conclusions
Surveillance with WB‐MRI is feasible from a psychosocial point of view both among TP53 carriers with as well as without a previous history of cancer and does not increase cancer worry in any of the groups. Plain language summary Individuals with heritable TP53 ‐related cancer syndrome (also known as the Li‐Fraumeni syndrome) have a high lifetime risk of developing cancer. These TP53 carriers are offered surveillance with whole‐body MRI to detect cancer early. There are few reports of the psychosocial impact of surveillance. In this study, we wanted to evaluate cancer worry, benefits and barriers to participation, and perceived overall health. Our study shows no increase in cancer worry after 1 year of surveillance, regardless of previous cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Cancer Theme, Karolinska University Hospital Solna, Stockholm, Sweden.
- Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden.
- Department of Radiation Sciences, Umeå University, Umeå, Sweden.
- Division of Clinical Genetics, Department of Laboratory Medicine, Office for Medical Services, Skåne University Hospital, Lund, Sweden.
- Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
ORCID-Profile: Meis Omran
Zitieren
APA
Omran, M., Johansson, H., Lundgren, C., Silander, G., Stenmark-Askmalm, M., Loman, N., Baan, A., Adra, J., Kuchinskaya, E., Blomqvist, L., Tham, E., Bajalica-Lagercrantz, S., Brandberg, Y., & Swedish Clinical TP53 Study Group (SweClinTP53) (2023). Whole‐body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study. Cancer. https://doi.org/10.1002/cncr.34631
Vancouver
Omran M, Johansson H, Lundgren C, Silander G, Stenmark-Askmalm M, Loman N, et al. Whole‐body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study. Cancer. 2023. doi:10.1002/cncr.34631
BibTeX
@article{Omran2023,
author = {Omran, Meis and Johansson, Hemming and Lundgren, Claudia and Silander, Gustav and Stenmark-Askmalm, Marie and Loman, Niklas and Baan, Annika and Adra, Jamila and Kuchinskaya, Ekaterina and Blomqvist, Lennart and Tham, Emma and Bajalica-Lagercrantz, Svetlana and Brandberg, Yvonne and Swedish Clinical TP53 Study Group (SweClinTP53), Swedish Clinical TP53 Study Group (SweClinTP53)},
title = {Whole‐body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34631}
}
EUVIMED